These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 12670296

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Current concepts in the biochemical assessment of the patient with acromegaly.
    Freda PU.
    Growth Horm IGF Res; 2003 Aug; 13(4):171-84. PubMed ID: 12914750
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pegvisomant: an advance in clinical efficacy in acromegaly.
    Stewart PM.
    Eur J Endocrinol; 2003 Apr; 148 Suppl 2():S27-32. PubMed ID: 12670298
    [Abstract] [Full Text] [Related]

  • 9. Correlation between GH and IGF-1 during treatment for acromegaly.
    Oldfield EH, Jane JA, Thorner MO, Pledger CL, Sheehan JP, Vance ML.
    J Neurosurg; 2017 Jun; 126(6):1959-1966. PubMed ID: 27858572
    [Abstract] [Full Text] [Related]

  • 10. Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal.
    Parkinson C, Kassem M, Heickendorff L, Flyvbjerg A, Trainer PJ.
    J Clin Endocrinol Metab; 2003 Dec; 88(12):5650-5. PubMed ID: 14671148
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Pregnancy-induced changes in insulin-like growth factor I (IGF-I), insulin-like growth factor binding protein 3 (IGFBP-3), and acid-labile subunit (ALS) in patients with growth hormone (GH) deficiency and excess.
    Wiesli P, Zwimpfer C, Zapf J, Schmid C.
    Acta Obstet Gynecol Scand; 2006 Dec; 85(8):900-5. PubMed ID: 16862465
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Monitoring of treatment success in patients with acromegaly: the value of serum insulin-like growth factor binding protein-3 and serum leptin measurements in comparison to plasma insulin-like growth factor I determination.
    Páramo C, Fluiters E, de la Fuente J, Andrade A, García-Mayor RV.
    Metabolism; 2001 Sep; 50(9):1117-21. PubMed ID: 11555849
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.